You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Investigators teased out imaging signals and underlying biology that can differentiate the subset of brain cancers for which tumor DNA can be detected in blood.
In a new study, using larger numbers of patient-specific mutations helped better detect residual disease in breast cancer patients' blood after treatment.
A four-year, $5.5 million program will assess whether circulating cell-free DNA testing can improve diagnosis and outcomes for a type of EBV-associated cancer.
The company has overcome one major hurdle and is poised to clear another in the first half of this year, clearing the way for new test development.
The firm said its revenues for the three months ended Dec. 31, 2019 were $62.9 million compared to $32.9 million in the same quarter of 2018.
Investigators have developed an approach called RAMP-Seq in which targeted radiation of a suspicious lesion vastly increase levels ctDNA, aiding detection and allowing genotyping.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
The group envisions using PGDx's technology to identify effective therapy options for cancer patients and improve monitoring of patient response to therapy.
The team plans to develop an assay that integrates circulating tumor cells and DNA to eliminate the need for repeated imaging surveillance in stage III melanoma patients.
Research is accumulating for the improved performance of epigenetic signals over mutations, with multiple commercial efforts well underway.
A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.
US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.
According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.
In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.